

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



廣州白雲山醫葯集團股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

## **ISSUE OF A SHARES PURSUANT TO THE PROPOSED PLACING**

### **INTRODUCTION**

References are made to the circular of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) dated 26 February 2015 (the “**2015 Circular**”) in relation to the Proposed Placing and the announcements and circular(s) of the Company in relation to the Proposed Placing issued subsequent to the Circular, including without limitation, the announcement of the Company dated 28 October 2015 whereby it was announced, among other things, that the offering size of the Proposed Placing had been reduced from approximately RMB10,000 million to approximately RMB8,300 million while the number of the new A Shares to be issued under the Proposed Placing had been adjusted from not more than 419,463,087 new A Shares to 352,292,020 new A Shares.

Unless otherwise defined, capitalised terms used in the 2015 Circular have the same meanings when used herein.

### **ISSUE OF A SHARES PURSUANT TO THE PROPOSED PLACING**

The Company hereby announces that it has completed the issue of an aggregate of 334,711,699 A Shares under the Proposed Placing. Save and except for the Asset Manager (as defined in the circular of the Company dated 16 February 2016) as trustee of the Employee Stock Trust, each Subscriber had subscribed for, and the Company has issued to it, the same number of new A Shares to be subscribed for by it under the Proposed Placing as set out in the section headed “Effects on the Shareholding Structure of the Company” in the announcement of the Company dated 26 November 2015. The Asset Manager (as trustee of the Employee Stock Trust) has subscribed for, and the Company has issued to it, 3,860,500 new A Shares, being the final aggregate number of A shares which the eligible participants of the Employee Stock Ownership Scheme (2015) subscribed for through the Asset

Manager. Set out below is a shareholding table demonstrating the shareholding structure of the Company immediately before and upon completion of the issue of the A Shares pursuant to the Proposed Placing:

Shareholders	Immediately before completion of the issue of the A Shares pursuant to the Proposed Placing		Immediately after completion of the issue of the A Shares pursuant to the Proposed Placing	
	<i>No. of Shares</i>	<i>%</i>	<i>No. of Shares</i>	<i>%</i>
<b>A Shares</b>				
<b>The Concert Group</b>				
GPHL	583,966,636	45.23	732,305,103	45.04
GZ SOA Development	–	–	87,976,539	5.41
GZ Chengfa	–	–	73,313,783	4.51
<b>Sub-total</b>	<u>583,966,636</u>	<u>45.23</u>	<u>893,595,425</u>	<u>54.96</u>
The Employee Stock Trust	–	–	3,860,500	0.24
<b>Public A Share Shareholders</b>				
Yunfeng Investment	–	–	21,222,410	1.31
Other public A Share Shareholders	487,212,614	37.74	487,212,614	29.97
<b>Sub-total</b>	<u>487,212,614</u>	<u>37.74</u>	<u>508,435,024</u>	<u>31.27</u>
<b>Total number of A Shares</b>	<u>1,071,179,250</u>	<u>82.97</u>	<u>1,405,890,949</u>	<u>86.47</u>
<b>H Shares</b>				
<b>Public H Share Shareholders</b>	<u>219,900,000</u>	<u>17.03</u>	<u>219,900,000</u>	<u>13.53</u>
<b>Total number of Shares</b>	<u>1,291,079,250</u>	<u>100.00</u>	<u>1,625,790,949</u>	<u>100.00</u>

The final total gross proceeds raised by the Company under the Proposed Placing is approximately RMB7,885 million. The final total net proceeds raised by the Company is approximately RMB7,863 million after deducting relevant expenses.

The Board of  
**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 18 August 2016

*As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong, Mr. Wu Changhai and Mr. Wang Wenchu as executive directors, and Mr. Wong Lung Tak Patrick, Mr. Qiu Hongzhong, Mr. Chu Xiaoping and Mr. Jiang Wenqi as independent non-executive directors.*